O-2694

O-2694

Identifiers
IUPAC name (6aR,10aR)-6,6,9-trimethyl-3-(2-methyl-7-morpholin-4-yl-7-oxoheptan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-yl 4-(di(propan-2-yl)amino)butanoate
PubChem (CID)	11714280
ChemSpider	9889001
Chemical and physical data
Formula	C38H60N2O5
Molar mass	624.891 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(N1CCOCC1)CCCCC(c3cc2OC([C@@H]4C/C=C(\C[C@H]4c2c(OC(=O)CCCN(C(C)C)C(C)C)c3)C)(C)C)(C)C
InChI InChI=1S/C38H60N2O5/c1-26(2)40(27(3)4)18-12-14-35(42)44-32-24-29(37(6,7)17-11-10-13-34(41)39-19-21-43-22-20-39)25-33-36(32)30-23-28(5)15-16-31(30)38(8,9)45-33/h15,24-27,30-31H,10-14,16-23H2,1-9H3/t30-,31-/m1/s1 Key:OAFUHIZKKMQSAB-FIRIVFDPSA-N
(what is this?)  (verify)

O-2694 is a drug that is a cannabinoid derivative. It has analgesic effects and is used in scientific research. Unlike most cannabinoids discovered to date, it is highly water-soluble, which gives it considerable advantages over many related drugs. It has high affinity for both CB₁ and CB₂ receptors, with K_i values of 3.7 nM at CB₁ and 2.8 nM at CB₂. However, it has complex pharmacokinetics as most of the administered dose is metabolised by hydrolysis of the ester link to the water-insoluble compound O-2372, thus producing a biphasic effects profile that is less suitable for research purposes than the related compound O-2545.^[1]

See also

• O-1057
• O-2372

References

1. Martin, B. R.; Wiley, J. L.; Beletskaya, I; Sim-Selley, L. J.; Smith, F. L.; Dewey, W. L.; Cottney, J; Adams, J; Baker, J; Hill, D; Saha, B; Zerkowski, J; Mahadevan, A; Razdan, R. K. (2006). "Pharmacological characterization of novel water-soluble cannabinoids". Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541.